Peptide Antibiotics Market Size, Trends, Share, Growth | Report 2022-2030
The global peptide antibiotics market was estimated at USD 4.4 billion in 2021 and it is expected to surpass around USD 6.86 billion by 2030, poised to grow at a CAGR of 5.06% from 2022 to 2030
Report Highlights
The market is expected to witness growth opportunities owing to factors such as the increasing research and development activities in field of peptide antibiotics coupled with high number of drug approvals. Moreover, surge in cases of antimicrobial resistance cases and possibility of side effects from the conventional antibiotics are also expected to drive the market during the forecast period.
Increasing prevalence of cancer and other infectious diseases are expected to propel the growth over the forecast period. For instance, according to the CDC, United States reported 1,752,735 new cancer cases along with 599,589 deaths in 2019. For every 100,000 people, 439 new cases were found and 146 people died due to cancer. Further, according to Globocan 2020, U.K. had 457,960 new cases with 179,648 deaths in 2020. The most common types of malignancies were breast, prostate cancer and Non-Hodgkin’s lymphoma.
There are some of the peptide antibiotics which are used to treat cancers such as, NHL, Hodgkin’s lymphoma, and certain types of skin malignancies. According to Globocan 2020, there were 5,44,352 Non-Hodgkin lymphoma cases and 83,087 Hodgkin’s lymphoma cases. The efficiency of various existing products is expected to result into higher revenues owing to doctor recommendations. For instance, BLEOMYCIN for injection USP is the mixture of cytotoxic glycopeptide antibiotics that is isolated from Streptomyces verticillus and is used for the treatment of testicular carcinoma, squamous cell carcinoma, and various types of lymphomas.
Moreover, ongoing product approvals and strategic initiatives undertaken by market players such as partnerships, collaborations, product launches, and expansions are expected to fuel market growth during forecast period. For instance, in July 2021, AbbVie Inc announced that the U.S. FDA approved DALVANCE for the treatment of acute bacterial skin and skin structure infections in pediatric patients from birth. Moreover, in July 2020, Sandoz International GmbH announced introduction of Daptomycin injection 500 mg, a generic version of Cubicin, in the U.S. market for the treatment of adult patients with complicated skin and skin structure infections and several type of bloodstream infections.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 4.4 billion |
| Revenue Forecast by 2030 | USD 6.86 billion |
| Growth rate from 2022 to 2030 | CAGR of 5.06% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Product type, disease, route of administration, distribution channel, region |
| Companies Covered | Pfizer Inc.; Merck & Co., Inc.; AbbVie Inc.; GSK Group of Companies; Sandoz International GmbH; Xellia Pharmaceuticals; AuroMedics Pharma LLC.; Theravance Biopharma |
Product Type Insights
The non-ribosomal synthesized peptide antibiotics segment held the largest revenue share of 72.4% in 2021 and is likely to maintain its dominance over the forecast period. The growth of the non-ribosomal synthesized peptide antibiotics is attributed by increasing demand for non-ribosomal synthesized antibiotics and rising availability of non-ribosomal synthesized antibiotics.
There are several non-ribosomal synthesized antibiotics available in market for peptide antibiotics. For instance, BLEOMYCIN (Glyco peptide product) manufactured by Pfizer Inc., is a non-ribosomal synthesized peptide antibiotic isolated from a strain of Streptomyces verticillus. BLEOMYCIN is used in the treatment of squamous cell carcinoma, testicular carcinoma, and lymphoma. Moreover, Bacitracin vial manufactured by Xellia Pharmaceuticals is indicated for the treatment of infants with pneumonia and empyema.
Disease Insights
The skin infection segment held the largest revenue share of 30.4% in 2021 and is likely to dominate the market during the forecast period. The growth of the skin infection segment is augmented by rising prevalence of skin infections such as, cellulitis, impetigo, furuncles, carcuncles, and others, and wide availability of products for treatment of bacterial skin infections. For instance, CUBICIN RF (daptomycin for injection) a type of lipo peptide product manufactured by Merck & Co., Inc. is used for the treatment of pediatric patients and adults with complicated skin and skin structure infections caused by S. aureus, S.pyrogenes, S. agalactiae.
However, the blood stream infection segment is anticipated to register fastest growth rate during the forecast period. The growth of the segment is augmented by rising incidences of blood stream infections, rising awareness about blood stream infections, and availability of robust product portfolio for management of blood stream infections. For instance, Polymyxin B vials manufactured by Xellia PHARMACEUTICALS is used for the treatment of blood-stream infections due to strains such as, E-Coli, Pseudomonas aeruginosa, H. influenza.
Distribution Channel Insights
The hospital pharmacies segment held the highest revenue share of 45.6% in 2021, whereas the retail pharmacies segment is expected to register fastest growth rate during the forecast period. Rising prescriptions of peptide antibiotics owing to various kind of bacterial skin infections, ophthalmic infections is a major factor expected to drive the retail pharmacy segment growth. However, the growth of hospital pharmacy segment is augmented by rising prevalence of blood stream infection, hospital acquired infection, and prolonged hospital stays.
Route Of Administration Insights
The injectable route of administration segment held the largest revenue share of 42.83% in 2021 and is expected to maintain its dominance during the forecast period. The growth of the injectable segment is attributed to factors such as availability of large number of peptide antibiotics in injectable form, efficiency, and better bioavailability from injectable peptide antibiotics.
There are a large number of products available in injectable form. For instance, DALVANCE manufactured by AbbVie Inc is administered by intravenous route as an infusion. DALVANCE is used for the treatment of various kind of skin infections. Moreover, vancomycin hydrochloride manufactured by Pfizer, Inc is given by IV infusion for the treatment of severe infections caused by susceptible strains of methicillin-resistant staphylococci.
Regional Insights
North America dominated the market for peptide antibiotics and accounted for revenue share of 40.95% in 2021 followed by Europe. Factors such as presence of large number of market players and strategic initiatives taken by key players are some of the major factors responsible for the growth.
Moreover, rising demand for antibiotics in this region, and increase in R&D activities in the region are also expected to drive the industry during the forecast period. Asia Pacific is expected to be the fastest growing region over the forecast period owing to factors such as increase in prevalence of various infectious diseases, rising geriatric population, and surge in awareness amongst patients about their health.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Peptide Antibiotics Market
5.1. COVID-19 Landscape: Peptide Antibiotics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Peptide Antibiotics Market, By Product Type
8.1. Peptide Antibiotics Market, by Product Type, 2022-2030
8.1.1. Ribosomal Synthesized Peptide Antibiotics
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Non-Ribosomal Synthesized Peptide Antibiotics
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Peptide Antibiotics Market, By Disease
9.1. Peptide Antibiotics Market, by Disease e, 2022-2030
9.1.1. Skin Infection
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. HABP/VABP
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Blood Stream Infection
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Peptide Antibiotics Market, By Route of Administration
10.1. Peptide Antibiotics Market, by Route of Administration, 2022-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Injectable
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Topical
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Peptide Antibiotics Market, By Distribution Channel
11.1. Peptide Antibiotics Market, by Distribution Channel, 2022-2030
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Peptide Antibiotics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.1.2. Market Revenue and Forecast, by Disease (2017-2030)
12.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Disease (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Disease (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.2.2. Market Revenue and Forecast, by Disease (2017-2030)
12.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Disease (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Disease (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Disease (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Disease (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.3.2. Market Revenue and Forecast, by Disease (2017-2030)
12.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Disease (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Disease (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Disease (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Disease (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.4.2. Market Revenue and Forecast, by Disease (2017-2030)
12.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Disease (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Disease (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Disease (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Disease (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.5.2. Market Revenue and Forecast, by Disease (2017-2030)
12.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Disease (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Disease (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Pfizer Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Merck & Co., Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. AbbVie Inc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. GSK Group of Companies
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Sandoz International GmbH
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Xellia Pharmaceuticals
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AuroMedics Pharma LLC
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Theravance Biopharma
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers